Clinical Trial Update: Early Access Program for Zolbetuximab

View source ↗

Summary

It provides an update on the Early Access Program for zolbetuximab in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Zolbetuximab (zolbetuximab)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Status: AVAILABLE